PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. President Obama then named her associate science director of the FDA’s Center for Devices and Radiological Health. McMurry-Heath was also a key science policy leader in government, conducting a comprehensive analysis of the National Science Foundation’s policies, programs and personnel. She came to BIO from Johnson & Johnson where she served as Global Head of Evidence Generation for Medical Device Companies and then Vice President of Global External Innovation and Global Leader for Regulatory Sciences. Michelle McMurry-Heath assumed the leadership of the Biotechnology Innovation Organization (BIO) as President and CEO in 2020. "As PerkinElmer enters its next chapter of growth following a year of significant portfolio transformation, I look forward to Michelle’s contributions to our overall vision and strategy moving ahead."Ī medical doctor and molecular immunologist by training, Dr. "I am pleased to welcome Michelle to PerkinElmer’s board and excited to see the Company benefit from both her deep research and advocacy experience along with her recognized leadership in influencing science policy and equitable access to medical innovation," said Alexis Michas, non-executive chairman of the board of PerkinElmer. Michelle McMurry-Heath has been elected to its board of directors, effective July 22, 2022. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Dr. PerkinElmer’s OneSource services and PerkinElmer Genomics operations enable this turnkey approach to provide sample testing in order to meet the Government’s COVID-19 testing requirements.WALTHAM, Mass., July 22, 2022-( BUSINESS WIRE)-PerkinElmer, Inc. This workflow solution enables rapid sample processing at higher volumes, helping to decrease turnaround time. PerkinElmer is utilising its chemagic 360 instruments and JANUS G3 PCR+ Workstations in UK labs to automate PerkinElmer’s RNA extraction and RT-PCR tests. Regular testing is a centrepiece of our roadmap back to normal life and sites like the Newport Lighthouse Laboratory are playing a pivotal role in our cautious easing of restrictions and continued efforts to send this virus into retreat.” We have now conducted over 166 million tests to date – more than any other European country – and this would not have been possible without the work of our partners such as PerkinElmer. Health minister Lord Bethell, added: “To help us face down this global pandemic, we have built the largest network of diagnostic testing facilities in British history, establishing the UK as a world-leader on testing. “The extension of the Newport Lighthouse laboratory’s contract will enable our specialist team to continue utilising our best-in-class technologies to ensure that maximum capacity will always align with NHS Test and Trace’s testing strategy, while also being able to quickly respond to evolving public health needs.” The contract extension will see the facility’s approximately 125 employees retained at the state-of-the-art facility, to maintain its capacity of delivering tens of thousands of tests daily.Īs the nation transitions out of lockdown, the contract extension will ensure that PerkinElmer solutions and expertise will remain available and able to respond as needed.Ĭhris Hughes, managing director UK & Ireland, PerkinElmer, said: “Testing is essential so that individuals carrying the virus can be rapidly detected and virus levels within communities can be monitored. Since being brought online in October 2020, the laboratory has processed over two million samples.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |